Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
WO29637
Phase 3 small_molecule completed
Quick answer
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody for Renal Cell Carcinoma is a Phase 3 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hoffmann-La Roche
- Indication
- Renal Cell Carcinoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed